Navigation Links
Aptuit and GSK Extend Strategic Partnership
Date:11/13/2012

GREENWICH, Conn., Nov. 13, 2012 /PRNewswire/ -- Aptuit LLC announced that the company has reached an agreement on a multiyear extension of its strategic partnership with GlaxoSmithKline (GSK) for dedicated drug development work at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The Verona site – formerly known as GSK's Medicines Research Centre – was acquired by Aptuit from GSK in 2010.

(Logo: http://photos.prnewswire.com/prnh/20120217/NY55633LOGO )

Timothy C. Tyson, Chairman, Aptuit LLC said, "This multiyear extension of our partnership with GSK reaffirms that our Verona site continues to deliver scientific excellence that is recognized by our customers. Since we finalized our original agreement with GSK in 2010, we have successfully transformed the Verona site from a pharmaceutical research center to a world-class drug discovery and development outsourcing capability."

Mr. Tyson explained that during the two years since the Verona site became part of Aptuit it has effectively transitioned to a lean, flexible, customer-focused pharmaceutical services operation. To date, the Verona site has had approximately 50 successful audits and has delivered work for more than 90 clients. Mr. Tyson added, "Aptuit initiatives in Verona, such as Lean Six Sigma, are resulting in productivity benefits across our business lines. The high level of quality and regulatory compliance demonstrated in our work has been noticeable to the more than 200 customers who have visited the site since 2010."

For additional press information or to arrange an interview, please contact Maria Garvey by phone at 914-747-1400 or send an email to maria@delfino.com.

Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Drug Product Formulation Development & Manufacture, Sterile Fill Finish, Clinical Sciences, Consulting and Aptuit INDiGO® (a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors.

For more information about Aptuit, visit www.aptuit.com


'/>"/>
SOURCE Aptuit LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aptuit Drug Discovery & Development Center In Verona, Italy Hits 100th Client Milestone
2. In Observance of Veterans Day Reproductive Medicine Associates of New Jersey Extends "Helping Heroes Build Families" Program
3. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
4. PDI, Inc. Announces $29 Million in New and Extended Sales Contracts
5. Qualitest Receives FDA Approval for Levetiracetam Extended-Release Tablets, 500mg and 750mg
6. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
7. MDHI Enhances Service Offerings with New Options for Customers of Americas Largest Warehouse Club Chain - Announces New Extended Concierge Services
8. Purdue Pharma L.P. Comments on FDA Announcement on REMS for Extended-Release and Long-Acting Opioid Analgesics
9. Heptares and UK Medical Research Council Extend GPCR Collaboration
10. Forum Extended Care Services Announces Plans to Move to Larger, State-Of-the-art Facility
11. Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , January 24, 2017 For today, ... GENE ), Alder Biopharmaceuticals Inc. (NASDAQ: ... ), and Egalet Corp. (NASDAQ: EGLT ). These ... lower on Monday, January 23 rd , 2017, with the ... health care companies in the S&P 500 also were down ...
(Date:1/24/2017)... YORK , Jan. 23, 2017 Laboratory ... the global use of mass spectrometry in both clinical ... current ,MS analysis, global market size of $6.8 billion ... the next four years, profiles the use of mass ... encompassing 21 countries. This study investigated growth in the ...
(Date:1/24/2017)... , January 23, 2017 ArisGlobal, ... life sciences, announces agClinical 3.3, the latest version of ... enables life science organizations to confidently and efficiently meet ... better manage the electronic trial master file so that ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... The health ... Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). 2016 was no ... Mainly, people are witnessing higher deductibles, rising premiums, and few choices with their ...
(Date:1/24/2017)... ... January 24, 2017 , ... PeroxyChem Food ... Assurance Control Equipment (PACE), at the International Production and Processing Expo (IPPE) in ... highlight the new technology that is used in poultry processing facilities to provide ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... was recently accepted as a Registered Trademark by the United States Patent and ... a similar name which could confuse consumers into thinking that other products are ...
(Date:1/24/2017)... ... January 24, 2017 , ... Learn to use popular ... or even in relationships. Course offered by Dr. Carol Francis at PVNET on ... limited seating and the many hands-on experiences. , Dr. Carol Francis shows ...
(Date:1/24/2017)... ... January 24, 2017 , ... Seceon , the ... in real-time, today announced a strategic partnership with Paramount , the Middle ... and protect their critical information assets and infrastructure, in a comprehensive and cost ...
Breaking Medicine News(10 mins):